Mutation Analysis (MutSig 2CV v3.1)
Thyroid Adenocarcinoma (Primary solid tumor)
28 January 2016  |  analyses__2016_01_28
Maintainer Information
Citation Information
Maintained by David Heiman (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2016): Mutation Analysis (MutSig 2CV v3.1). Broad Institute of MIT and Harvard. doi:10.7908/C16W99KN
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig 2CV v3.1 was used to generate the results found in this report.

  • Working with individual set: THCA-TP

  • Number of patients in set: 496

Input

The input for this pipeline is a set of individuals with the following files associated for each:

  1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

  2. A .wig file that contains information about the coverage of the sample.

Summary
  • MAF used for this analysis:THCA-TP.final_analysis_set.maf

  • Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt

  • Significantly mutated genes (q ≤ 0.1): 30

Results
Lego Plots

The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.

Figure 1.  Get High-res Image SNV Mutation rate lego plot for entire set. Each bin is normalized by base coverage for that bin. Colors represent the six SNV types on the upper right. The three-base context for each mutation is labeled in the 4x4 legend on the lower right. The fractional breakdown of SNV counts is shown in the pie chart on the upper left. If this figure is blank, not enough information was provided in the MAF to generate it.

Figure 2.  Get High-res Image SNV Mutation rate lego plots for 4 slices of mutation allele fraction (0<=AF<0.1, 0.1<=AF<0.25, 0.25<=AF<0.5, & 0.5<=AF) . The color code and three-base context legends are the same as the previous figure. If this figure is blank, not enough information was provided in the MAF to generate it.

CoMut Plot

Figure 3.  Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

  • nnon = number of (nonsilent) mutations in this gene across the individual set

  • npat = number of patients (individuals) with at least one nonsilent mutation

  • nsite = number of unique sites having a non-silent mutation

  • nsil = number of silent mutations in this gene across the individual set

  • p = p-value (overall)

  • q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 1.  Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 30. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank gene longname codelen nnei nncd nsil nmis nstp nspl nind nnon npat nsite pCV pCL pFN p q
1 BRAF v-raf murine sarcoma viral oncogene homolog B1 2371 4 0 2 290 0 0 1 291 291 3 1.5e-14 1e-05 1e-05 1e-16 3.7e-13
2 NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 590 34 0 0 40 0 0 0 40 40 2 4e-16 1e-05 0.0031 1e-16 3.7e-13
3 HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 659 493 0 0 17 0 0 0 17 17 2 1e-16 1e-05 0.0018 1e-16 3.7e-13
4 NUDT11 nudix (nucleoside diphosphate linked moiety X)-type motif 11 500 92 0 0 0 0 0 10 10 10 1 1e-16 1e-05 1 1e-16 3.7e-13
5 RPTN repetin 2363 99 0 1 2 0 0 9 11 10 6 8.7e-14 1e-05 0.011 1e-16 3.7e-13
6 EMG1 EMG1 nucleolar protein homolog (S. cerevisiae) 754 507 0 0 0 0 0 11 11 11 2 1.7e-11 1e-05 0.89 6.3e-15 1.9e-11
7 FAM47C family with sequence similarity 47, member C 3110 106 0 2 15 0 0 0 15 14 4 7.8e-09 1e-05 0.82 2.4e-12 6.3e-09
8 EIF1AX eukaryotic translation initiation factor 1A, X-linked 459 178 0 0 5 1 3 0 9 7 7 1.5e-09 4e-05 0.34 3.6e-12 8.2e-09
9 DLX6 distal-less homeobox 6 890 90 0 0 0 0 0 7 7 7 3 1.2e-09 0.0006 1 4.5e-11 9e-08
10 GPR44 G protein-coupled receptor 44 1192 7 0 0 0 0 0 4 4 4 2 6.4e-08 0.0001 0.73 3.2e-10 5.8e-07
11 TMEM184A transmembrane protein 184A 1272 425 0 0 0 0 0 5 5 5 1 0.000016 1e-05 1 3.9e-09 6.4e-06
12 NUP93 nucleoporin 93kDa 2544 111 0 0 1 3 0 0 4 4 2 1.4e-06 0.0003 0.23 9.2e-09 0.000014
13 GAGE2A G antigen 2A 1486 13 0 0 1 0 0 3 4 4 2 8.9e-07 0.0005 0.91 1.1e-08 0.000016
14 ABL1 c-abl oncogene 1, receptor tyrosine kinase 3573 20 0 1 1 0 0 4 5 5 2 0.000017 4e-05 0.18 1.9e-08 0.000024
15 LMTK2 lemur tyrosine kinase 2 4564 6 0 0 1 0 0 3 4 4 2 0.000068 0.0001 0.66 1.3e-07 0.00016
16 SRPX sushi-repeat-containing protein, X-linked 1431 257 0 0 1 0 0 3 4 4 2 0.00014 0.00014 0.99 4.1e-07 0.00047
17 PPM1D protein phosphatase 1D magnesium-dependent, delta isoform 1838 124 0 0 1 0 0 5 6 6 6 1.1e-07 1 0.86 1.8e-06 0.002
18 TG thyroglobulin 8498 86 0 5 8 0 0 13 21 21 21 2.9e-07 1 0.74 4.7e-06 0.0047
19 PTCD1 pentatricopeptide repeat domain 1 2131 114 0 0 0 1 0 2 3 3 2 0.000046 0.0074 0.92 5.5e-06 0.0052
20 TSC22D1 TSC22 domain family, member 1 3357 43 0 1 1 0 0 3 4 4 2 0.0042 0.0001 0.93 6.6e-06 0.006
21 AKT1 v-akt murine thymoma viral oncogene homolog 1 1495 19 0 1 5 0 0 0 5 5 3 0.0018 0.00062 0.23 0.000013 0.011
22 ZNF878 zinc finger protein 878 1753 70 0 0 4 0 0 0 4 4 1 0.0095 0.0001 1 0.000014 0.012
23 RBM10 RNA binding motif protein 10 2881 106 0 1 4 0 0 0 4 4 1 0.011 0.0001 1 0.000016 0.012
24 OR2T29 olfactory receptor, family 2, subfamily T, member 29 930 5 0 0 0 0 0 2 2 2 2 1e-05 1 0.065 0.000016 0.012
25 EP400 E1A binding protein p400 9577 53 0 2 1 0 0 3 4 4 2 0.011 0.0001 0.68 0.000016 0.012
26 ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 2274 64 0 0 3 1 0 0 4 4 4 0.000028 NaN NaN 0.000028 0.019
27 MYH10 myosin, heavy chain 10, non-muscle 6091 2 0 0 1 1 0 2 4 4 3 0.0014 0.0022 0.83 0.000041 0.028
28 NLRP6 NLR family, pyrin domain containing 6 2706 77 0 0 4 0 0 0 4 4 2 0.033 0.0001 0.0091 0.000044 0.029
29 IGSF3 immunoglobulin superfamily, member 3 3685 16 0 1 4 0 0 0 4 4 2 0.066 0.0001 0.44 0.000085 0.054
30 PRMT8 protein arginine methyltransferase 8 1221 27 0 0 3 0 0 0 3 3 2 0.0011 0.011 1 0.00015 0.092
31 ARMCX3 armadillo repeat containing, X-linked 3 1140 157 0 0 0 1 0 2 3 3 2 0.0018 0.01 0.92 0.00022 0.13
32 OR56A1 olfactory receptor, family 56, subfamily A, member 1 961 52 0 0 2 0 0 0 2 2 2 0.0019 1 0.01 0.00022 0.13
33 RYR1 ryanodine receptor 1 (skeletal) 15537 42 0 2 8 0 0 0 8 8 7 0.001 0.018 0.95 0.00025 0.14
34 TNRC18 trinucleotide repeat containing 18 9019 3 0 0 1 0 0 3 4 4 4 0.00015 1 0.14 0.00028 0.15
35 TMEM90B 789 57 0 0 0 0 0 3 3 3 1 0.025 0.001 0.88 0.00029 0.15
BRAF

Figure S1.  This figure depicts the distribution of mutations and mutation types across the BRAF significant gene.

NRAS

Figure S2.  This figure depicts the distribution of mutations and mutation types across the NRAS significant gene.

HRAS

Figure S3.  This figure depicts the distribution of mutations and mutation types across the HRAS significant gene.

RPTN

Figure S4.  This figure depicts the distribution of mutations and mutation types across the RPTN significant gene.

FAM47C

Figure S5.  This figure depicts the distribution of mutations and mutation types across the FAM47C significant gene.

EIF1AX

Figure S6.  This figure depicts the distribution of mutations and mutation types across the EIF1AX significant gene.

DLX6

Figure S7.  This figure depicts the distribution of mutations and mutation types across the DLX6 significant gene.

TMEM184A

Figure S8.  This figure depicts the distribution of mutations and mutation types across the TMEM184A significant gene.

NUP93

Figure S9.  This figure depicts the distribution of mutations and mutation types across the NUP93 significant gene.

ABL1

Figure S10.  This figure depicts the distribution of mutations and mutation types across the ABL1 significant gene.

LMTK2

Figure S11.  This figure depicts the distribution of mutations and mutation types across the LMTK2 significant gene.

SRPX

Figure S12.  This figure depicts the distribution of mutations and mutation types across the SRPX significant gene.

PPM1D

Figure S13.  This figure depicts the distribution of mutations and mutation types across the PPM1D significant gene.

TG

Figure S14.  This figure depicts the distribution of mutations and mutation types across the TG significant gene.

PTCD1

Figure S15.  This figure depicts the distribution of mutations and mutation types across the PTCD1 significant gene.

TSC22D1

Figure S16.  This figure depicts the distribution of mutations and mutation types across the TSC22D1 significant gene.

AKT1

Figure S17.  This figure depicts the distribution of mutations and mutation types across the AKT1 significant gene.

ZNF878

Figure S18.  This figure depicts the distribution of mutations and mutation types across the ZNF878 significant gene.

RBM10

Figure S19.  This figure depicts the distribution of mutations and mutation types across the RBM10 significant gene.

OR2T29

Figure S20.  This figure depicts the distribution of mutations and mutation types across the OR2T29 significant gene.

EP400

Figure S21.  This figure depicts the distribution of mutations and mutation types across the EP400 significant gene.

ABCD1

Figure S22.  This figure depicts the distribution of mutations and mutation types across the ABCD1 significant gene.

MYH10

Figure S23.  This figure depicts the distribution of mutations and mutation types across the MYH10 significant gene.

NLRP6

Figure S24.  This figure depicts the distribution of mutations and mutation types across the NLRP6 significant gene.

IGSF3

Figure S25.  This figure depicts the distribution of mutations and mutation types across the IGSF3 significant gene.

PRMT8

Figure S26.  This figure depicts the distribution of mutations and mutation types across the PRMT8 significant gene.

Methods & Data
Methods

MutSig and its evolving algorithms have existed since the youth of clinical sequencing, with early versions used in multiple publications. [1][2][3]

"Three significance metrics [are] calculated for each gene, using the […] methods MutSigCV [4], MutSigCL, and MutSigFN [5]. These measure the significance of mutation burden, clustering, and functional impact, respectively […]. MutSigCV determines the P value for observing the given quantity of non-silent mutations in the gene, given the background model determined by silent (and noncoding) mutations in the same gene and the neighbouring genes of covariate space that form its 'bagel'. […] MutSigCL and MutSigFN measure the significance of the positional clustering of the mutations observed, as well as the significance of the tendency for mutations to occur at positions that are highly evolutionarily conserved (using conservation as a proxy for probably functional impact). MutSigCL and MutSigFN are permutation-based methods and their P values are calculated as follows: The observed nonsilent coding mutations in the gene are permuted T times (to simulate the null hypothesis, T = 108 for the most significant genes), randomly reassigning their positions, but preserving their mutational 'category', as determined by local sequence context. We [use] the following context categories: transitions at CpG dinucleotides, transitions at other C-G base pairs, transversions at C-G base pairs, mutations at A-T base pairs, and indels. Indels are unconstrained in terms of where they can move to in the permutations. For each of the random permutations, two scores are calculated: SCL and SFN, measuring the amount of clustering and function impact (measured by conservation) respectively. SCL is defined to be the fraction of mutations occurring in hotspots. A hotspot is defined as a 3-base-pair region of the gene containing many mutations: at least 2, and at least 2% of the total mutations. SFN is defined to be the mean of the base-pair-level conservation values for the position of each non-silent mutation […]. To determine a PCL, the P value for the observed degree of positional clustering, the observed value of SCL (computed for the mutations actually observed), [is] compared to the distribution of SCL obtained from the random permutations, and the P value [is] defined to be the fraction of random permutations in which SCL [is] at least as large as the observed SCL. The P value for the conservation of the mutated positions, PFN, [is] computed analogously." [6]

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References
[1] Getz G, Höfling H, Mesirov JP, Golub TR, Meyerson M, Tibshirani R, Lander ES, Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers", Science 317(5844):1500b (2007)
[3] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474(7353):609-615 (2011)
[4] Lawrence MS, et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature 499(7457):214-218 (2013)
[6] Lawrence MS, et al., Discovery and saturation analysis of cancer genes across 21 tumour types, Nature 505(7484):495-501 (2014)